Encouraging the use of generics is only one of the ways to manage the rising costs of medications, according to Karen Ignagni, president and CEO of EmblemHealth. Data and system transparency will also help both the patients and the payers better understand this growing trend.
Encouraging the use of generics is only one of the ways to manage the rising costs of medications, according to Karen Ignagni, president and CEO of EmblemHealth. Data and system transparency will also help both the patients and the payers better understand this growing trend.
Transcript (slightly modified)
How has EmblemHealth been helping its customers manage the rising cost of drugs?
This is a very important issue, I’m glad you’re raising it. The rising cost of drugs—probably the most challenging policy issue in the healthcare arena today. And the reason for that is that in many situations where we have very high costs being propelled by companies that are single-source companies for those drugs. So we have a monopoly and we’re negotiating against a monopoly and it’s very hard to negotiate against a monopoly.
So the question is, what do you do? We try to create formulary structures that encourage the use of generics, although we’ve seen those costs exploding recently. We’ve seen the cost of the regular drugs that most of the population is using explode, lately. But we try to create formularies that encourage the access providing individuals a pathway to address their needs, giving them choice and letting them make choices. And, having a series of structures around them that support that with information, with transparency, and making sure that in the end, they feel that they are well supported and have their medical needs met on the pharmaceutical side.
But this whole issue of what drug for what condition—how do you look at a drug to drug, a drug to a therapy to another type of procedure or a device, for example? We really have very little data that is objectively produced and in the public domain. We need access data, we need efficiency data, we need quality performance data, and we need cost data. And we can’t run from that because individuals themselves, their households, are spending a significant amount of money in this area. Employers are spending a significant amount of money, as are states and the federal government. So we need to have better data, number 1.
We need more transparency. How much is being allocated for R&D versus profits that are at the 40% and 50% level or even higher in the case of the hepatitis drugs. That’s something the American people have a right to know. And I think that that provides transparency in the public arena so that we can have the kind of informed conversation that we need to have as Americans in this arena.
So we’re hoping that we will continue to be able to partner with pharmaceutical companies on value-based strategies but at the same time, we can’t ignore the exploding costs. And the American people, obviously, are not ignoring the exploding costs.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More